LeMaitre Vascular, Inc. LMAT
76.10 USD -0.91 (-1.18%)
Regular-session close
76.10 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
75.67 Day range 77.53
75.67 52-week range 118.01
- YTD
- -6.17%
- 1 year
- -12.52%
News
benzinga.com Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $86 Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $94 to $86.
benzinga.com Citizens Maintains Market Outperform on LeMaitre Vascular, Lowers Price Target to $110 Citizens analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and lowers the price target from $127 to $110.
benzinga.com LeMaitre Vascular Q3 2026 Earnings Call Transcript LeMaitre Vascular (NASDAQ:LMAT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 Est; Narrows FY2026 Sales Guidance from $274.300M-$278.300M to $274.800M-$276.800M vs $276.539M Est LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.84-$2.94 to $2.77-$2.82 vs $2.87 analyst estimate. Narrows FY2026 sales outlook from $274.300 million-$278.300 million to…
benzinga.com LeMaitre Vascular Lowers Q4 GAAP EPS Guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 Est; Lowers Q4 Sales Guidance from $71.100M-$73.100M to $69.900M-$71.900M vs $72.325M Est LeMaitre Vascular (NASDAQ:LMAT) lowers Q4 GAAP EPS guidance from $0.75-$0.81 to $0.70-$0.75 vs $0.78 analyst estimate. Lowers Q4 sales outlook from $71.100 million-$73.100 million to $69.900…
